Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ASTX 029

Next Previous
Drug Profile

ASTX 029

Alternative Names: ASTX-029

Latest Information Update: 29 Mar 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Astex Pharmaceuticals
  • Class Amides; Amines; Antineoplastics; Halogenated hydrocarbons; Phenyl ethers; Pyrans; Pyrimidines; Small molecules
  • Mechanism of Action Mitogen activated protein kinase 3 inhibitors; Mitogen-activated protein kinase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Solid tumours
  • Preclinical Acute myeloid leukaemia; Uveal melanoma

Most Recent Events

  • 29 Feb 2024 M.D. Anderson Cancer Center plans a phase I/II trial for Myelodysplastic syndromes (Combination therapy, Second-line therapy or greater) and Myelofibrosis in USA (PO), in July 2024 (NCT06284460)
  • 27 Oct 2023 M.D. Anderson Cancer Center plans a phase Ib/IIa trial of ASTX 029 (Combination therapy, Second-line therapy or greater) in acute myeloid leukemia in USA (PO) in April 2024 (NCT06113289)
  • 11 Oct 2023 Pharmacodynamics data from preclinical studies in Solid tumours presented at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2023 (AACR-NCI-EORTC-2023)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top